Novo Nordisk presents positive results from SOUL cardiovascular outcomes trial of Rybelsus at ACC's annual scientific ...
Novo Nordisk presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular …